Potential coronavirus treatment granted rare disease status

Gilead Sciences CEO Daniel O’Day speaks at a March 2 meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House. (AP Photo/Andrew Harnik)

WASHINGTON — The pharmaceutical giant that makes a promising coronavirus drug has registered it as a rare disease treatment with U.S. regulators, a status that can potentially be worth millions in tax breaks and competition-free sales.